FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression

New approval based on KEYNOTE-021, Cohort G1, results INDIANAPOLIS, June 5, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a ... Biopharmaceuticals, Oncology, FDA Eli Lilly, ALIMTA, pemetrexed, KEYTRUDA, NSCLC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news